Compare Gilead Sciences, Inc. (GILD) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kaltura Inc — how do they compare? Gilead Sciences, Inc. trades at $134.68 (market cap $163.51B), while Kaltura Inc trades at $1.3 (market cap $195.49M). The key difference: Gilead Sciences, Inc. is far larger — about 836.4× Kaltura Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| GILD | KLTR | |
|---|---|---|
Market Cap | $163.51B | $195.49M |
Sector | Health | Technology |
52-Week High | $155.80 | $1.97 |
52-Week Low | $108.22 | $1.08 |
Enterprise Value | $178.05B | $178.21M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Kaltura (KLTR) trades at $1.30, up 2.36% today, showing positive momentum despite a bearish technical signal. The company continues to beat earnings expectations with three consecutive quarterly EPS beats, though it remains unprofitable with a -8.25% net margin. Recent industry recognition includes Frost & Sullivan Global Company of the Year and multiple Gartner leadership positions, highlighting strong competitive positioning in digital experience platforms.
While Kaltura demonstrates improving financial trends with narrowing losses and positive operating cash flow, the stock faces headwinds from persistent unprofitability and high P/B ratio of 42.09. Analyst sentiment is mixed with 44% buy ratings, but technical indicators suggest near-term caution. The company's AI-driven product innovations provide growth catalysts, but execution risk remains elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
